Insider Selling: Walter C. Herlihy Sells 60,335 Shares of Repligen Corp. Stock (RGEN)
Repligen Corp. (NASDAQ:RGEN) CEO Walter C. Herlihy unloaded 60,335 shares of the stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $20.11, for a total value of $1,213,336.85. Following the completion of the sale, the chief executive officer now directly owns 539,477 shares in the company, valued at approximately $10,848,882. The sale was disclosed in a filing with the SEC, which is available at this link.
RGEN has been the subject of a number of recent research reports. Analysts at Jefferies Group raised their price target on shares of Repligen Corp. from $20.00 to $22.00 in a research note on Wednesday, June 4th. They now have a “buy” rating on the stock.
Shares of Repligen Corp. (NASDAQ:RGEN) traded down 1.41% on Thursday, hitting $19.54. The stock had a trading volume of 359,202 shares. Repligen Corp. has a 52 week low of $7.37 and a 52 week high of $21.15. The stock’s 50-day moving average is $17.97 and its 200-day moving average is $15.02. The company has a market cap of $626.0 million and a P/E ratio of 35.46.
Repligen Corp. (NASDAQ:RGEN) last announced its earnings results on Thursday, May 8th. The company reported $0.13 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.07 by $0.06. The company had revenue of $16.33 million for the quarter, compared to the consensus estimate of $15.14 million. Repligen Corp.’s revenue was down .8% compared to the same quarter last year. On average, analysts predict that Repligen Corp. will post $0.28 earnings per share for the current fiscal year.
Repligen Corporation is a United States-based life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.